{"id":"NCT03097133","sponsor":"Janssen Research & Development, LLC","briefTitle":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide","officialTitle":"A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-15","primaryCompletion":"2019-04-11","completion":"2019-04-11","firstPosted":"2017-03-31","resultsPosted":"2020-09-25","lastUpdate":"2025-04-29"},"enrollment":230,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Esketamine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"OTHER","name":"Standard of Care","otherNames":[]}],"arms":[{"label":"Esketamine + Standard of care","type":"EXPERIMENTAL"},{"label":"Placebo + Standard of care","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.","primaryOutcome":{"measure":"Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase","timeFrame":"Baseline (Day 1, predose) and 24 hours first post dose (Day 2)","effectByArm":[{"arm":"Placebo + Standard of Care (SOC)","deltaMin":-12.4,"sd":10.43},{"arm":"Esketamine 84 mg + SOC","deltaMin":-15.7,"sd":11.56}],"pValues":[{"comp":"OG000 vs OG001","p":"0.006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":61,"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","Czechia","France","Lithuania","Poland","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["37568081","37439961","35904046","35816217","34510411","32861217"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217051&parentIdentifier=CR108285&attachmentIdentifier=6345e95c-007a-4ab5-b5f6-736c8099e66f&fileName=54135419SUI3002_(CR108285)_Additional_Results_Data_CH.pdf&versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":113},"commonTop":["Dizziness","Nausea","Dissociation","Headache","Dysgeusia"]}}